|
1
|
Weber JS, O‘Day S, Urba W, Powderly J,
Nichol G, Yellin M, Snively J and Hersh E: Phase I/II study of
ipilimumab for patients with metastatic melanoma. J Clin Oncol.
26:5950–5956. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hodi FS, O‘Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pericord VA, Montalvo W, Leiner IM and
Allison JP: Single dose of anti-CTLA-4 enhances CD8 T-cell memory
formation, function, and maintenance. Proc Natl Acad Sci USA.
108:261–271. 2011.
|
|
7
|
Wang W, Lau R, Yu D, Zhu W, Korman A and
Weber J: PD1 blockade reverses the suppression of melanoma
antigen-specific CTL by CD4+ CD25(Hi) regulatory T
cells. Int Immunol. 21:1065–1077. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sznol M and Chen L: Antagonist antibodies
to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human
cancer. Clin Cancer Res. 19:1021–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Okazaki T, Chikuma S, Iwai Y, Fagarasan S
and Honjo T: A rheostat for immune responses: The unique properties
of PD-1 and their advantages for clinical application. Nat Immunol.
14:1212–1218. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weber JS, D‘Angelo SP, Minor D, Hodi FS,
Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD,
et al: Nivolumab versus chemotherapy in patients with advanced
melanoma who progressed after anti-CTLA-4 treatment (CheckMate
037): A randomised, controlled, open-label, phase 3 trial. Lancet
Oncol. 16:375–384. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
John LB, Devaud C, Duong CP, Yong CS,
Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH and Darcy PK:
Anti-PD-1 antibody therapy potently enhances the eradication of
established tumors by gene-modified T cells. Clin Cancer Res.
19:5636–5646. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mangsbo SM, Sandin LC, Anger K, Korman AJ,
Loskog A and Tötterman TH: Enhanced tumor eradication by combining
CTLA-4 or PD-1 blockade with CpG therapy. J Immunother. 33:225–235.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nakamura Y, Tai S, Oshita C, Iizuka A,
Ashizawa T, Saito S, Yamaguchi S, Kondo H, Yamaguchi K and Akiyama
Y: Analysis of HLA-A24-restricted peptides of carcinoembryonic
antigen using a novel structure-based peptide-HLA docking
algorithm. Cancer Sci. 102:690–696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Akiyama Y, Komiyama M, Nakamura Y, Iizuka
A, Oshita C, Kume A, Nogami M, Miyata H, Ashizawa T, Yoshikawa S,
et al: Identification of novel MAGE-A6- and MAGE-A12-derived
HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in
silico peptide-docking assay. Cancer Immunol Immunother.
61:2311–2319. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iizuka A, Komiyama M, Oshita C, Kume A,
Ashizawa T, Mitsuya K, Hayashi N, Nakasu Y, Yamaguchi K and Akiyama
Y: Anti-vascular endothelial growth factor receptor (VEGFR) 2
autoantibody identification in glioblastoma patient using single B
cell-based antibody gene cloning. Immunol Lett. 159:15–22. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Callahan MK, Wolchok JD and Allison JP:
Anti-CTLA-4 antibody therapy: Immune monitoring during clinical
development of a novel immunotherapy. Semin Oncol. 37:473–484.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Topalian SL, Sznol M, McDermott DF, Kluger
HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB,
Powderly JD, et al: Survival, durable tumor remission, and
long-term safety in patients with advanced melanoma receiving
nivolumab. J Clin Oncol. 32:1020–1030. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ascierto PA, Simeone E, Sznol M, Fu YX and
Melero I: Clinical experiences with anti-CD137 and anti-PD1
therapeutic antibodies. Semin Oncol. 37:508–516. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vonderheide RH, Flaherty KT, Khalil M,
Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ,
Gallagher M, Kramer A, et al: Clinical activity and immune
modulation in cancer patients treated with CP-870,893, a novel CD40
agonist monoclonal antibody. J Clin Oncol. 25:876–883. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Melero I, Grimaldi AM, Perez-Gracia JL and
Ascierto PA: Clinical development of immunostimulatory monoclonal
antibodies and opportunities for combination. Clin Cancer Res.
19:997–1008. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mahoney KM, Freeman GJ and McDermott DF:
The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in
melanoma. Clin Ther. 37:764–782. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Larkin J, Chiarion-Sileni V, Gonzaliz R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ascierto PA, Kalos M, Schaer DA, Callahan
MK and Wolchok JD: Biomarkers for immunostimulatory monoclonal
antibodies in combination strategies for melanoma and other tumor
types. Clin Cancer Res. 19:1009–1020. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Simeone E, Gentilcore G, Giannarelli D,
Grimaldi AM, Caracò C, Curvietto M, Esposito A, Paone M, Palla M,
Cavalcanti E, et al: Immunological and biological changes during
ipilimumab treatment and their potential correlation with clinical
response and survival in patients with advanced melanoma. Cancer
Immunol Immunother. 63:675–683. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brahmer J, Reckamp KL, Baas P, Crino L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rizvi NA, Mazières J, Planchard D,
Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E,
Mennecier B, et al: Activity and safety of nivolumab, an anti-PD-1
immune checkpoint inhibitor, for patients with advanced, refractory
squamous non-small-cell lung cancer (CheckMate 063): A phase 2,
single-arm trial. Lancet Oncol. 16:257–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Das R, Verma R, Sznol M, Boddupalli CS,
Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R,
Dhodapkar MV, et al: Combination therapy with anti-CTLA-4 and
anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol.
194:950–959. 2015. View Article : Google Scholar
|
|
28
|
Wang C, Thudium KB, Han M, Wang XT, Huang
H, Feingersh D, Garcia C, Wu Y, Kuhne M, Srinivasan M, et al: In
vitro characterization of the anti-PD-1 antibody nivolumab,
BMS-936558, and in vivo toxicology in non-human primates. Cancer
Immunol Res. 2:846–856. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang J, Guo W and Liang X: Phenotypes,
accumulation, and functions of myeloid-derived suppressor cells and
associated treatment strategies in cancer patients. Hum Immunol.
75:1128–1137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Markowitz J, Brooks TR, Duggan MC, Paul
BK, Pan X, Wei L, Abrams Z, Luedke E, Lesinski GB, Mundy-Bosse B,
et al: Patients with pancreatic adenocarcinoma exhibit elevated
levels of myeloid-derived suppressor cells upon progression of
disease. Cancer Immunol Immunother. 64:149–159. 2015. View Article : Google Scholar :
|
|
31
|
Klein O, Ebert LM, Nicholaou T, Browning
J, Russell SE, Zuber M, Jackson HM, Dimopoulos N, Tan BS, Hoos A,
et al: Melan-A-specific cytotoxic T cells are associated with tumor
regression and autoimmunity following treatment with anti-CTLA-4.
Clin Cancer Res. 15:2507–2513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wong RM, Scotland RR, Lau RL, Wang C,
Korman AJ, Kast WM and Weber JS: Programmed death-1 blockade
enhances expansion and functional capacity of human melanoma
antigen-specific CTLs. Int Immunol. 19:1223–1234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Weber JS, Kudchadkar RR, Yu B, Gallenstein
D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, et
al: Safety, efficacy, and biomarkers of nivolumab with vaccine in
ipilimumab-refractory or -naïve melanoma. J Clin Oncol.
31:4311–4318. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ribas A, Comin-Anduix B, Chmielowski B,
Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva
A, Oseguera DK, et al: Dendritic cell vaccination combined with
CTLA4 blockade in patients with metastatic melanoma. Clin Cancer
Res. 15:6267–6276. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Inoue M, Senju S, Hirata S, Irie A, Baba H
and Nishimura Y: An in vivo model of priming of antigen-specific
human CTL by Mo-DC in NOD/Shi-scid IL2rgamma(null) (NOG) mice.
Immunol Lett. 126:67–72. 2009. View Article : Google Scholar : PubMed/NCBI
|
